Targeted Medical Pharma Stock

Targeted Medical Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Targeted Medical Pharma (TRGM) as of Aug 6, 2026 is -4.08. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 4.75 — a change of -185.79% (lower).

EV/FCF

-4.08

YoY

-185.79%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Targeted Medical Pharma is 2026 -4.08 . EV/FCF (Enterprise Value to Free Cash Flow) of Targeted Medical Pharma was 2025 4.75 . It decreases by -185.79% lower compared to the previous year.
Access this data via the Eulerpool API

Targeted Medical Pharma Stock analysis

What does Targeted Medical Pharma do? Targeted Medical Pharma Inc is a California-based biotechnology company that focuses on the development and marketing of patented pharmaceutical products in the field of neuroscience and pulmonology. The company was founded in 1999 and has since placed emphasis on the development of patented pharmaceutical products that can be used in various medical areas. The main business model of Targeted Medical Pharma is to bring innovative product developments to the market that can bridge the gap between conventional medicine and integrative medicine. The company aims to create therapy options that are very specific to certain diseases, which can then be patented and marketed. However, disposable drugs (medicines that need to be administered once a year and then have long-term effects), as one knows from other companies, are not used. The company offers a wide range of different divisions and products that have been developed over the years. The main divisions covered by Targeted Medical Pharma include: 1. Neurology: Here, the company develops products for the treatment of neurological disorders such as ADHD, Alzheimer's, autism, depression, stroke, and other diseases of the central nervous system. 2. Pain management: In this division, Targeted Medical Pharma focuses on the development of products against chronic pain, back pain, and migraines. 3. Sports medicine: The goal of this division is to help athletes improve their performance and recovery and to prevent injuries. 4. Pulmonology: Here, Targeted Medical Pharma offers products targeting the treatment of lung problems such as asthma and COPD. Some of the well-known products developed by Targeted Medical Pharma include: 1. Sentra AM: A dietary supplement specifically developed to support the nervous system and used for the treatment of depression, anxiety, and other neurological disorders. 2. Theramine: A patented amino acid mixture developed for chronic pain, supporting the body in pain relief and fighting inflammation. 3. Aeropur: An inhalation device specifically developed for the treatment of asthma and COPD. 4. Clearwayz: A solution that helps loosen mucus and clear airways during colds and bronchitis. 5. Trepadone: A dietary supplement developed in collaboration with the US Navy to reduce inflammation and muscle soreness after intense physical training and improve recovery. The company has earned great respect in the industry and among investors, particularly through the continuous development of new products and emphasis on scientific research and clinical evidence. A seven-figure number of patients can benefit from these innovations. Targeted Medical Pharma has worked on the development of more than 25 different patented pharmaceutical products, several of which have already been approved by the FDA (Food and Drug Administration). The company has also established numerous valuable connections with academic institutions and healthcare facilities, which is expected to benefit the development of new and innovative products. Overall, Targeted Medical Pharma is a company specializing in patented product development. In fact, it is working hard to revolutionize the complementary medicine field by creating innovative therapies and treatments to have a lasting positive impact on the health and well-being of millions of people worldwide. Targeted Medical Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Targeted Medical Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Targeted Medical Pharma is -4.08 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Targeted Medical Pharma changed from 4.75 to -4.08, representing a -185.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Targeted Medical Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Targeted Medical Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Targeted Medical Pharma

All Key Metrics — Targeted Medical Pharma